Order Article Reprints

Bencsik K, Dobos E, Jobbágy Z, Birkás AJ, Kovács K, Sátori M, Lencsés G, Bartok G, Losonczi E, Vécsei L, et al. Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study. Pharmaceuticals. 2022; 15(5):598. https://doi.org/10.3390/ph15050598

Bencsik, Krisztina, Enikő Dobos, Zita Jobbágy, Adrienne Jóri Birkás, Krisztina Kovács, Mária Sátori, Gyula Lencsés, Gabor Bartok, Erika Losonczi, László Vécsei, and et al. 2022. "Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study" Pharmaceuticals 15, no. 5: 598. https://doi.org/10.3390/ph15050598

Bencsik, K., Dobos, E., Jobbágy, Z., Birkás, A. J., Kovács, K., Sátori, M., Lencsés, G., Bartok, G., Losonczi, E., Vécsei, L., & on behalf of the Teri-REAL Investigators. (2022). Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study. Pharmaceuticals, 15(5), 598. https://doi.org/10.3390/ph15050598